Skip to content
ABOUT
AUTHOR GUIDELINES
AUTHORS/EDITORS
SUBSCRIPTIONS
CONTACT US
MY ACCOUNT
Facebook
X
LinkedIn
Instagram
Search
×
HOME
PSYCH. BULLETIN
LATEST ISSUE
BLACK BOOK OF DOSING & MONITORING
RATING SCALES
LICENSING INFORMATION
RESOURCES
PSYCHOTROPICS A-Z
PSYCHOPHARMACOLOGY 101
NEWS
Drug Development for Anxiety Disorders: New Roles for Atypical Antipsychotics
1
x
$
30.00
Vicki L. Ellingrod, PharmD, BCPP: 5-HT2A Receptor Promoter Polymorphism, -1438G/A and Negative Symptom Response to Olanzapine in Schizophrenia
1
x
$
30.00
Advancing the Treatment of Anxiety Disorders: New Findings and Novel Uses for Atypical Antipsychotics
1
x
$
30.00
Vicki L. Ellingrod, PharmD, BCPP: Leptin and Leptin Receptor Gene Polymorphisms and Increases in Body Mass Index (BMI) from Olanzapine Treatment in Persons with Schizophrenia
1
x
$
30.00
Consistently Modest Antidepressant Effects in Clinical Trials: the Role of Regulatory Requirements (OPEN ACCESS)
1
x
$
0.00
Psychopharmacology Bulletin VOL 47 No. 1, 2017 - Full Issue Stacked PDF
1
x
$
60.00
View Cart
Checkout
Home
reversible-encephalopathy
“Psychopharmacology Bulletin VOL 47 No. 1, 2017 – Full Issue Stacked PDF” has been added to your cart.
View cart
Sort by
Date
Sort by
Name
Sort by
Price
Sort by
Date
Sort by
Popularity
Show
20 Products
Show
20 Products
Show
40 Products
Show
60 Products
Reversible Encephalopathy due to Valproic Acid Induced Hyperammonemia in a Patient with Bipolar I Disorder: A Cautionary Report
$
30.00
Add to cart
Details
Psychopharmacology Bulletin VOL 47 No. 1, 2017 – Full Issue Stacked PDF
$
60.00
Add to cart
Details
Page load link
Go to Top
